$ACHR

The Pentagon Is Buying eVTOLs. Here's Which Stock Wins the Defense Money.

The Pentagon has awarded contracts to Archer Aviation (up to $142M) and Joby Aviation (up to $131M) for eVTOL aircraft. Archer's Midnight aircraft is already delivered, while Joby is adapting to DoD's shift toward hybrid and autonomous tech. Archer's partnership with Anduril and potential acquisition of Boeing's Insitu may give it an edge in defense contracts.

Original reporting
Published Sep 26, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 26, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Pentagon Is Buying eVTOLs. Here's Which Stock Wins the Defense Money. — source image
Decision brief

The 30-second read

$ACHRBullishHigh
01

Why it matters

The disclosed contracts and acquisitions represent the first public disclosure of these specific deals, providing fresh material for traders.

02

Market read

New defense contracts and acquisitions could re‑price Archer and Joby, with Archer likely benefiting more.

03

What to watch

Potential integration challenges with multiple Boeing assets and reliance on future Pentagon budget allocations.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Pentagon’s Agility Prime program is pivoting toward hybrid and autonomous eVTOLs, prompting both Archer and Joby to adjust strategies.

Company-level read

Ticker impact

$ACHRBullishHigh confidence
Context

Archer Aviation received a Pentagon Agility Prime contract valued up to $142 million and announced a partnership with Anduril and a planned acquisition of Boeing's Insitu, Wisk Aero, and SkyGrid businesses.

Expected impact

likely upside as the market prices in the new defense revenue opportunity.

Evidence & confidence

The contract and acquisition news are fresh, sizable, and directly increase Archer's defense exposure.

$JOBYNeutralMedium confidence
Context

Joby Aviation disclosed a $131 million Air Force contract, plans to acquire defense contractor Resonant Sciences for ~$500 million, and a shift toward hybrid and autonomous aircraft.

Expected impact

possible pressure as investors weigh reduced contract scope against the acquisition.

Evidence & confidence

The acquisition is new, but the reduced contract scope tempers the upside.

Market effects

Strengthens the defense‑aerospace and eVTOL sectors, highlighting Pentagon spending on hybrid/autonomous aircraft.

U.S. defense contractors may see increased demand; European eVTOL peers could face competitive pressure.

Signals a shift toward hybrid‑electric military UAVs worldwide.

Counterpoint

Archer's contract is not guaranteed revenue and the new platform is unproven, so the upside may be limited.

Key entities

  • Archer Aviation

    U.S. eVTOL manufacturer receiving a $142 M defense contract.

  • Joby Aviation

    U.S. eVTOL maker with a $131 M Air Force contract and a $500 M acquisition.

  • Pentagon / U.S. Air Force

    Awarding contracts through the Agility Prime program.

Related articles

$ACHRMed

Archer Aviation’s Turbulent Week Hides Big Defense Bet

Archer Aviation (ACHR) shares fell 13.22% this week. Goldman Sachs cut its price target to $7, citing FAA certification risks and defense revenue timing. Barclays upgraded to Overweight, highlighting defense potential. Archer reported a $263.2M net loss last quarter. Analysts maintain a Strong Buy consensus with upside potential.

$ACHRMed

Archer Stock Sinks After Goldman Sachs Slashes Price Target to $

Archer Aviation (ACHR) shares dropped 5% after Goldman Sachs cut its price target to $7 from $8, citing valuation concerns and commercial operation uncertainties. The analyst reduced the 2030 revenue multiple to 2.5x from 3x, despite improved earnings forecasts. Goldman expects Archer's 2028 loss to narrow to $1.27 per share and 2030 loss to $0.16 per share. Execution risks include aircraft certification and production levels.

$JOBYMed

4 High-Risk Stocks Built for Big Returns

Joby Aviation aims to be a transportation-as-a-service company with its eVTOL aircraft, making progress with FAA-compliant and autonomous technology. Viking Therapeutics is developing obesity drug VK2735, showing promising weight loss data in trials. Both companies are high-risk, high-reward investments.

$JOBYMed

Why Did ASTS, CIFR, JOBY Stocks Plunge To 52-Week Lows Today?

Joby Aviation (JOBY) reported a larger-than-expected Q2 loss of $0.25 per share, raising concerns about its financial resources. Barclays downgraded JOBY to 'Underweight', questioning its market potential and production capacity. ASTS, CIFR, and JOBY stocks have fallen 23-62% this year. Retail sentiment remains bullish despite the downturn.

$JOBYMed

What Just Happened To Joby Stock?

Joby Aviation (JOBY) stock fell 68.4% in the year to October 12, 2026, despite the S&P 500 gaining 20.5%. Key events included a Goldman Sachs Sell rating, broader market adjustments, and a $116.9M damages ruling. Joby's Q2 2026 revenue was $39M, with a net loss of $245M. The company has $2.3B in cash and plans to spend $385M-$415M in the second half of 2026.